CFAR Overview ABSTRACT This competing renewal application for the Penn Center for AIDS Research (CFAR) builds on an outstanding record of dynamic scientific leadership, organizational structure, resources and infrastructure that advance HIV/AIDS research across the integrated campus of the University of Pennsylvania, Children's Hospital of Philadelphia & the Wistar Institute. The CFAR's mission is to catalyze cutting-edge science and add value to the AIDS research enterprise through activities that could not be achieved by individual investigators or research projects. The Center is comprised of 250 members from our 3 institutions, including 11 of the 12 Penn schools and 17 departments within the School of Medicine, and key partners. The success of the CFAR in the last 5 years is reflected in >$200M in AIDS-related NIH funding over that time, key discoveries in AIDS research priority areas including HIV cure, vaccine development, immune reservoirs, bio-behavioral prevention & engagement in care, HIV coinfections/comorbidities & other areas, and 3 interdisciplinary Scientific Working Groups with high impact outcomes including funding of a Martin Delaney Collaboratory. Looking ahead, a comprehensive strategic planning process has led us to refine CFAR priorities, Core activities, and Core leadership to leverage new expertise and cultivate new research leaders, and maintain a cutting-edge focus for our SWGs. The Penn CFAR is now well-positioned to address critical challenges during the next 5 years. Our CFAR recently established two new SWGs (?Technology to Reduce HIV Disparities? & ?HIV Reservoirs & Tissue Immunology?) that have already achieved high impact discoveries and will be carried forward to the next cycle. The CFAR supports a Developmental Core and 7 Shared Resource Cores (Clinical, Virus & Reservoirs, Immunology, Prevention Science & Community Outreach, Biostatistics & Data Science, Nonhuman Primate, and International) that provide essential support for the research mission. The CFAR is led by Drs. Ronald Collman (Director) and Robert Gross (Co-Director) and governed by an Executive Committee with input from an Internal Advisory Board, External Advisory Committee and Community Advisory Board. The Penn CFAR has 4 highly inter-linked Specific Aims that enable it to achieve its mission: (1) Provide scientific and administrative leadership and pilot funding to catalyze innovative, interdisciplinary research that will lead to new knowledge and solutions for the AIDS crisis; (2) Attract, train, mentor and support the next generation of HIV/AIDS researchers to ensure forward-looking scientific progress, draw non-AIDS investigators into the field with cross-cutting interdisciplinary expertise, and launch the next generation of research leaders; (3) Support, monitor and continually evolve a set of efficient, dynamic & innovative Shared Resource Cores that both support HIV/AIDS investigators and lead the research agenda through development & dissemination of innovative technology that transforms scientific capacity, and; (4) Advance science and synergy through intra- campus, local, national & international partnerships, community engagement and capacity building.

Public Health Relevance

The CFAR's mission is to advance cutting-edge HIV/AIDS research on the Penn/CHOP/Wistar campus that will contribute innovative solutions to the AIDS crisis. The CFAR achieves this mission by providing scientific and administrative leadership to generate new research directions and collaborations; providing shared resource cores that support research through critical enabling technologies; leveraging institutional resources; training and mentoring the next generation of researchers and leaders and attracting scientists from other fields; and establishing partnerships and generating synergy with other groups on campus, in Philadelphia, nationally and internationally.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI045008-22
Application #
9925274
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Wong, Elaine Wai-Ken
Project Start
1999-07-01
Project End
2024-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Brocca-Cofano, Egidio; Xu, Cuiling; Wetzel, Katherine S et al. (2018) Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques. J Virol 92:
Costea, Paul I; Hildebrand, Falk; Arumugam, Manimozhiyan et al. (2018) Enterotypes in the landscape of gut microbial community composition. Nat Microbiol 3:8-16
Page, Kathleen R; Grieb, Suzanne Dolwick; Nieves-Lugo, Karen et al. (2018) Enhanced immigration enforcement in the USA and the transnational continuity of HIV care for Latin American immigrants in deportation proceedings. Lancet HIV 5:e597-e604
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Opondo, Philip R; Ho-Foster, Ari R; Ayugi, James et al. (2018) HIV Prevalence Among Hospitalized Patients at the Main Psychiatric Referral Hospital in Botswana. AIDS Behav 22:1503-1516
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Clarke, Erik L; Lauder, Abigail P; Hofstaedter, Casey E et al. (2018) Microbial Lineages in Sarcoidosis. A Metagenomic Analysis Tailored for Low-Microbial Content Samples. Am J Respir Crit Care Med 197:225-234

Showing the most recent 10 out of 775 publications